Welcome and Comments from DMAS' Director
Cheryl Roberts, JD Medicaid Director

Call to Order

Drug Utilization Review (DUR) Board Update

Approval of Minutes from March 16, 2023, Meeting

P&T Committee Members
P&T Committee Members

Old business

Phase II – New Drug Review (Therapeutic Class)

Brand Drugs
- Vowst™ (Antibiotics, GI)
- Inpefa™ (Hypoglycemics, SGLT2) (Closed Class)
- Brixadi™ (Opiate Dependence Treatments) (Closed Class)

Biosimilar for Humira
- Adalimumab-Adaz
- Hyrimoz®
- Hadlima®
- Yuflyma®
- Adalimumab-Fkjp Pen®
- Hulio®
- Cyltezo®
- Idacio®
- Yusimry (Cf)®

Generics Drugs and New Dosage Forms
- Vancomycin 25 Mg/Ml Solution (Antibiotics, GI)

PDL Phase I – Annual Review -

Antibiotics/Anti-Infectives
- Antibiotics, Vaginal

Antivirals
- Hepatitis C Agents (Closed Class)
- HIV (Closed Class)

Blood Modifiers
- Bile Acid Salts
- Hemophilia Treatment (Closed Class)
- Phosphate Binders
- Sickle Cell Anemia Treatments (Closed Class)
Cardiac Medications

- Angiotensin Modulator Combinations
- Angiotensin Modulators II (includes Direct Renin Inhibitors & combination products)
- Antihypertensives, Sympatholytics
- Beta Blockers (includes combination products)
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)
- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Lipotropics, Statins
- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable (includes Endothelin-1 agents, PDE-5 Inhibitors, Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators

Central Nervous System

- Anticonvulsants (Closed class)
- Antipsychotics (includes oral and long acting injectables) (Closed class) (was reviewed in the spring of 2023 but is a fall class and is being moved back to the fall)
- Antidepressants, SSRI
- Antidepressants, Other
- Movement Disorders (Closed Class)
- Sedative Hypnotics

Dermatitis

- Immunomodulators, Atopic Dermatitis (Closed Class)
- Steroids, Topical

Endocrine & Metabolic Agents Oral

- Glucocorticoids, Oral
- Growth Hormones (Closed Class)
- Glucagon Agents (Closed Class)
- HAE Treatments
- Progestins for Cachexia
- Weight Management Agents (Closed Class)

Gastrointestinal

- Antiemetic/Antivertigo Agents
- GI Motility, Chronic
- H. pylori Agents
- Histamine II Receptor Antagonists
- Proton Pump Inhibitors
- Ulcerative Colitis

Genitourinary

- Bladder Relaxants
- BPH Agents

Ophthalmic

- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)
- Ophthalmic, Anti-Inflammatory/Immunomodulator (Closed Class)
- Ophthalmic, Glaucoma

Respiratory
• Anti-Allergens, Oral
• Antibiotics, Inhaled
• Antihistamines, Minimally Sedating
• Bronchodilators, Beta Agonist
  a. Bronchodilators, Long-Acting Beta Adrenergics
  b. Bronchodilators, Short Acting Beta Adrenergics
• COPD Agents (Closed Class)
• Cough & Cold Agents (Legend)
• Epinephrine, Self-Injected
• Glucocorticoids (includes nebulized solutions, metered dose inhalers and combinations) (Closed Class)
• Intranasal Rhinitis (includes Antihistamines and Corticosteroids)
• Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion) P&T Committee Members & DMAS Staff
PDL Recommendations and Vote P&T Committee Members
Criteria Discussion of Phase II New Drugs* P&T Committee Members
Criteria Discussion of PDL Phase I Drug Classes* P&T Committee Members

Next Meeting - tentatively scheduled for March 21, 2024.

*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.

Oral Presentations: The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL Phase I drugs in classes which are scheduled for review at the September meeting and new PDL Phase II drugs listed on the Agenda. All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

• PDL Phase I Annual Reviews – September 2022 to present
• New Drugs in PDL Phase I or II Drug Classes – September 2021 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on Thursday, August 24, 2023.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST on Thursday, August 24, 2023.

.